.jpg/1600px-Former_Commissioner_Stephen_Hahn_(49484140217).jpg)
Community hub
Recent from talks
Knowledge base stats:
Talk channels stats:
Members stats:
Stephen Hahn
Stephen Michael Hahn (born January 22, 1960) is an American physician who served as the commissioner of food and drugs from 2019 to 2021. Before becoming commissioner, he was an oncologist serving as chief medical executive of the MD Anderson Cancer Center. In 2021, he became chief medical officer at Flagship Pioneering, the venture capital firm that launched Moderna.
Hahn received a BA in Biology from Rice University in 1980, and an MD from Temple University in 1984. After graduating from medical school, Hahn completed an internal medicine residency at the University of California, San Francisco School of Medicine where he eventually served as chief resident before embarking on a fellowship in medical oncology at the National Institutes of Health (NIH).
After completing his fellowship, Hahn worked as a radiation oncologist in Santa Rosa, California. He was then recruited by his mentor, Eli J. Glatstein to complete a separate residency in radiation oncology at the NIH between 1991 and 1994, where he eventually attained the rank of commander in the U.S. Public Health Service Commissioned Corps between 1989 and 1995. During the period of 1993–1999, he served as chief of NCI's Prostate Cancer Clinic in the Clinical Pharmacology Branch.
In 1996, Hahn joined the University of Pennsylvania School of Medicine as a radiation and medical oncologist as well as a researcher funded by the National Institutes of Health (NIH). As eventual Vice-Chair for Research in the Department of Radiation Oncology at Penn and Principal Investigator of National Cancer Institute grants, Hahn led the expansion of the Department's research base. In 2013, he was awarded status as a fellow in the American Society for Radiation Oncology (ASTRO). He then held the Department of Radiation Oncology's fourth endowed Henry Pancoast Professorship as Department Chair until 2014.[1][permanent dead link] During that time, Hahn assisted with the Department's scandal involving brachytherapy at the Veterans Affairs Hospital in Philadelphia, which was staffed with University of Pennsylvania faculty, all while securing increased research funding during a transition period in 2007-08 into the new Perelman Center for Advanced Medicine Robert's Proton Center, which remains the largest proton therapy center associated with a university teaching hospital in the world. Hahn remains Board Certified in Internal Medicine, Medical Oncology, and Radiation Oncology.
In 2015, Hahn became the chair of radiation oncology at the University of Texas MD Anderson Cancer Center in Houston, where he oversaw the Departments of Clinical Radiation Oncology, Radiation Physics, and Radiation Biology. In 2018, Hahn was appointed as the Chief Medical Executive of MD Anderson Cancer Center. During this period as an active clinician, Hahn specialized in treating thoracic, sarcomatous, and genitourinary cancers, as well as the use of photodynamic therapy for the treatment of pre-invasive and invasive malignancies.
On November 1, 2019, U.S. President Donald Trump announced his intent to nominate Hahn to be Commissioner of Food and Drugs Administration. On December 3, 2019, the Senate Health Education Labor and Pensions Committee voted 18 to 5 to advance the nomination to the Senate floor. On December 12, 2019, the Senate confirmed his nomination by a 72–18 vote. Hahn was sworn in on December 17, 2019.
Hahn has factored prominently in the Trump administration's response to the novel coronavirus pandemic in the United States, although the FDA under his administration has also been criticized for a lethargic response to the rapidly emerging outbreak in the United States. By November 2020, Hahn had gained the confidence of individuals concerned about the politicization of the agency.
On March 1, 2020, Vice President Mike Pence and Health and Human Services Secretary Alex Azar announced the addition of Hahn to the White House Coronavirus Task Force.
Hub AI
Stephen Hahn AI simulator
(@Stephen Hahn_simulator)
Stephen Hahn
Stephen Michael Hahn (born January 22, 1960) is an American physician who served as the commissioner of food and drugs from 2019 to 2021. Before becoming commissioner, he was an oncologist serving as chief medical executive of the MD Anderson Cancer Center. In 2021, he became chief medical officer at Flagship Pioneering, the venture capital firm that launched Moderna.
Hahn received a BA in Biology from Rice University in 1980, and an MD from Temple University in 1984. After graduating from medical school, Hahn completed an internal medicine residency at the University of California, San Francisco School of Medicine where he eventually served as chief resident before embarking on a fellowship in medical oncology at the National Institutes of Health (NIH).
After completing his fellowship, Hahn worked as a radiation oncologist in Santa Rosa, California. He was then recruited by his mentor, Eli J. Glatstein to complete a separate residency in radiation oncology at the NIH between 1991 and 1994, where he eventually attained the rank of commander in the U.S. Public Health Service Commissioned Corps between 1989 and 1995. During the period of 1993–1999, he served as chief of NCI's Prostate Cancer Clinic in the Clinical Pharmacology Branch.
In 1996, Hahn joined the University of Pennsylvania School of Medicine as a radiation and medical oncologist as well as a researcher funded by the National Institutes of Health (NIH). As eventual Vice-Chair for Research in the Department of Radiation Oncology at Penn and Principal Investigator of National Cancer Institute grants, Hahn led the expansion of the Department's research base. In 2013, he was awarded status as a fellow in the American Society for Radiation Oncology (ASTRO). He then held the Department of Radiation Oncology's fourth endowed Henry Pancoast Professorship as Department Chair until 2014.[1][permanent dead link] During that time, Hahn assisted with the Department's scandal involving brachytherapy at the Veterans Affairs Hospital in Philadelphia, which was staffed with University of Pennsylvania faculty, all while securing increased research funding during a transition period in 2007-08 into the new Perelman Center for Advanced Medicine Robert's Proton Center, which remains the largest proton therapy center associated with a university teaching hospital in the world. Hahn remains Board Certified in Internal Medicine, Medical Oncology, and Radiation Oncology.
In 2015, Hahn became the chair of radiation oncology at the University of Texas MD Anderson Cancer Center in Houston, where he oversaw the Departments of Clinical Radiation Oncology, Radiation Physics, and Radiation Biology. In 2018, Hahn was appointed as the Chief Medical Executive of MD Anderson Cancer Center. During this period as an active clinician, Hahn specialized in treating thoracic, sarcomatous, and genitourinary cancers, as well as the use of photodynamic therapy for the treatment of pre-invasive and invasive malignancies.
On November 1, 2019, U.S. President Donald Trump announced his intent to nominate Hahn to be Commissioner of Food and Drugs Administration. On December 3, 2019, the Senate Health Education Labor and Pensions Committee voted 18 to 5 to advance the nomination to the Senate floor. On December 12, 2019, the Senate confirmed his nomination by a 72–18 vote. Hahn was sworn in on December 17, 2019.
Hahn has factored prominently in the Trump administration's response to the novel coronavirus pandemic in the United States, although the FDA under his administration has also been criticized for a lethargic response to the rapidly emerging outbreak in the United States. By November 2020, Hahn had gained the confidence of individuals concerned about the politicization of the agency.
On March 1, 2020, Vice President Mike Pence and Health and Human Services Secretary Alex Azar announced the addition of Hahn to the White House Coronavirus Task Force.